Physician profile
Michael A Jantz
NPI 1225077159
$188,887.67
in general payments reported to CMS, 2019-2025
19 companies · $24K in 2025
The $24K reported for 2025 was more than what 96% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,183 · 2020: $357 · 2021: $9,282 · 2022: $59K · 2023: $54K · 2024: $42K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $56K · Education: $48K · Travel and Lodging: $7,827 · Food and Beverage: $5,000 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $56,336.00 |
| Education | $48,202.09 |
| Travel and Lodging | $7,827.44 |
| Food and Beverage | $5,000.14 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $122,975.07 | 2021-2024 | Da Vinci Surgical System, Da Vinci Sp |
| Ge Healthcare | $61,077.40 | 2023-2025 | |
| Pulmonx Corporation | $2,229.24 | 2019-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Astrazeneca Pharmaceuticals LP | $571.56 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Galvanize Therapeutics, INC | $484.22 | 2023-2024 | Aliya System |
| Glaxosmithkline, LLC. | $463.43 | 2022-2025 | Nucala, Trelegy Ellipta |
| Pinnacle Biologics, INC | $402.51 | 2022-2023 | Photofrin |
| Ethicon INC. | $303.15 | 2021 | |
| Ani Pharmaceuticals, INC. | $132.19 | 2025 | Purified Cortrophin Gel |
| Amgen INC. | $84.93 | 2024-2025 | Tezspire |
| Insmed, INC. | $71.72 | 2025 | Arikayce, Brinsupri |
| Lilly USA, LLC | $35.42 | 2023-2025 | Zepbound, Jardiance |
| Auris Health, INC. | $32.04 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.60 | 2025 | Jascayd |
| Veran Medical Technologies, INC. | $7.19 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$4,672.50 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.